
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics is attractive fundamentally because LTI-03 has a differentiated Caveolin-1-based mechanism that aims to both suppress profibrotic signaling and preserve alveolar epithelial cells, a profile that could offer more than existing antifibrotics in IPF. The investment case has also strengthened materially as the $57.5M financing removed the near-term funding overhang, with $43.6M in cash, cash equivalents and marketable securities at 2Q26 and expected runway into 1Q28, allowing the market to focus on execution rather than dilution risk. With RENEW already above 25% enrollment, all five planned countries enrolling, and initial/interim data expected in 2H26, the stock now has a credible near-term catalyst to test whether promising Phase 1b biomarker activity can translate into clinically meaningful benefit.
Bears say
Rein Therapeutics is viewed negatively because its valuation depends heavily on an early-stage LTI-03 program assigned only a 30% probability of success, reflecting prior setbacks in idiopathic pulmonary fibrosis, while the company still needs to extend its limited cash runway to finish the ongoing Phase 2 trial. The DCF framework also embeds caution through a 14.1% WACC, a 4.0x exit multiple to 2036 estimates, and a -8.7% terminal growth rate, signaling muted long-term confidence and constrained upside assumptions. Additional concerns include 57.5M new shares from the recent raise, financing and regulatory risk, competition before LTI-03 launch, and the stock trading near $1, which creates bid compliance risk.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Rein Therapeutics Inc (RNTX) Forecast
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares